About Us

OneVax, LLC is a pre-clinical biotechnology company located in Alachua, Florida developed to harness the intellectual and research advances of University of Florida faculty for applications in the advancement of human health, and specifically, type 1 diabetes. Members of the UF Diabetes Institute and the Department of Biomedical Engineering constitute the core membership and provide the scientific direction of the company. The initial business interests of the company involve the development of novel vaccine formulations that incorporate biomaterials and polymers for applications including multicomponent and time-release drug delivery.  The core goal of OneVax is to harness our knowledge of the immune system and biomaterials to create a tolerogenic vaccine to prevent and/or reverse type 1 diabetes.